CABERGOLINE Tablets, 0.5 mg, RX only, 8 count bottles, Manufactured For: TEVA PHARMACEUTICALS USA, Sellersville, PA 18960 NDC 0093-5420-88

Impurities/Degradation Products: This lot of product will not meet the impurity specification over shelf life

Recall #: D-128-2013
Affected scope: 13,232 bottles
Initiated: April 24, 2012

Compiled from official public sources by the publisher. · Updated September 2026

Teva Pharmaceuticals USA, Inc. recalled CABERGOLINE Tablets, 0.5 mg, RX only, 8 count bottles, Manufactured For: TEVA PHARMACEUTI… - a low-severity action.

CABERGOLINE Tablets, 0.5 mg, RX only, 8 count bottles, Manufactured For: TEVA PHARMACEUTI… was recalled by Teva Pharmaceuticals USA, Inc. in January 23, 2013. Reason: Impurities/Degradation Products: This lot of product will not meet the impurity specification over shelf life. Check the official notice for the remedy. Verify recall #D-128-2013 with the FDA Drug before acting.

The recall

Teva Pharmaceuticals USA, Inc. issued this low-severity FDA Drug recall-Impurities/Degradation Products: This lot of product will not meet the impurity specification over shelf life.

Low
severity level: Class III
classification: January 23, 2013
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-128-2013 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified low severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

CABERGOLINE Tablets, 0.5 mg, RX only, 8 count bottles, Manufactured For: TEVA PHARMACEUTICALS USA, Sellersville, PA 18960 NDC 0093-5420-88

Reason for recall

Impurities/Degradation Products: This lot of product will not meet the impurity specification over shelf life

Recall Profile

Structured summary of the FDA Drug recall record
Attribute	Value
Agency	U.S. Food and Drug Administration
Severity class	Low (Class III)
Status	Terminated
Recall number	D-128-2013
Date reported	January 23, 2013
Date initiated	April 24, 2012
Recalling firm	Teva Pharmaceuticals USA, Inc.
Firm location	Sellersville, PA
Affected scope	13,232 bottles
Distribution	Nationwide

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

Check the recall number (D-128-2013) and product description against the item you own. Search the archive
Confirm the current status with FDA Drug before acting, recall details can be updated.
Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled? ▼

CABERGOLINE Tablets, 0.5 mg, RX only, 8 count bottles, Manufactured For: TEVA PHARMACEUTICALS USA, Sellersville, PA 18960 NDC 0093-5420-88. Recalled by Teva Pharmaceuticals USA, Inc.. Units affected: 13,232 bottles.

Why was this product recalled? ▼

Impurities/Degradation Products: This lot of product will not meet the impurity specification over shelf life

Which agency issued this recall? ▼

This recall was issued by the FDA Drug on January 23, 2013. Severity: Low. Recall number: D-128-2013.

Where was the recalled product distributed? ▼

Distribution: Nationwide.

Should I stop using a recalled medication or medical device? ▼

Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Similar severity · nearest report date

Same archive severity grade (Low), closest by report date among other firms and states.

Perindopril Erbumine Tablets, 8mg, 100 Ta… 2013-01-23 Divalproex Sodium Delayed-Release Tablets… 2013-01-23 Fresenius GranuFlo Dry Acid Concentrate F… 2013-01-23 Fresenius GranuFlo Naturalyte Dry Acid C… 2013-01-23

Similar Household Products · nearest report date

Same product category, closest by report date among other firms and states (deduped against the severity set).

Mattress Cloud Recalls Mattresses Due to … 2013-01-23 Siemens Recalls Temperature and Humidity … 2013-01-22 Floor Lamps Recalled by Dolan Northwest D… 2013-01-17 Powertec Recalls Weight Workbenches Due t… 2013-01-16

Compare this recall with CCM Hockey U.S. Recalls FMHVR Hybrid Visors and ACCHVR Repl… → · All Household Products recalls

This recall: FDA Drug, reported January 23, 2013. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026